In this GEN webinar, experts from ChemPartner, Philip Clarke, PhD, Hu Liu, PhD, and Greg Liang, MD, will provide an overview of some of the innovative platforms that are shaping the next-generation of ...
Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...
Success is no longer just about prolonging survival, but about enabling patients to live well after cancer, with fewer ...
Zacks Investment Research on MSN
Can OPKO Health's pipeline progress and deals drive growth in 2026?
OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism ...
Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
CStone Pharmaceuticals' IND application has received FDA clearance, enabling the company to initiate a Phase II trial of its trispecific antibody CS2009.
US FDA clears CStone’s IND application for novel trispecific antibody CS2009 to advance into phase II trial: Suzhou, China Tuesday, February 17, 2026, 11:00 Hrs [IST] CStone Pha ...
CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate ...
SAN FRANCISCO and SUZHOU, China, Jan. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results